PDSB — PDS Biotechnology Balance Sheet
0.000.00%
- $63.03m
- $43.17m
Annual balance sheet for PDS Biotechnology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 28.8 | 65.2 | 73.8 | 56.6 | 41.7 |
Prepaid Expenses | |||||
Total Current Assets | 30.3 | 66.8 | 76.5 | 59.1 | 45.1 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.553 | 0.358 | 0.528 | 0.335 | 0.304 |
Total Assets | 30.9 | 67.2 | 77 | 59.4 | 45.4 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3.27 | 3.76 | 9.82 | 13.6 | 17.1 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 3.76 | 3.99 | 33 | 33.3 | 26.4 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 27.1 | 63.2 | 44 | 26.1 | 19 |
Total Liabilities & Shareholders' Equity | 30.9 | 67.2 | 77 | 59.4 | 45.4 |
Total Common Shares Outstanding |